

Zolpidem Dependence : A case report

Satyakam Mohapatra, Nihar Ranjan Rath, Neelmadhav Rath Mental Health Institute, S.C.B. Medical College, Cuttack

ABSTRACT

Zolpidem, a nonbenzodiazepine hypnotic, binds to the benzodiazepine binding site on the gamma-aminobutyric acid type A (GABA-A) receptors. Many studies have reported efficacy and safety of zolpidem in treatment of insomnia, low abuse, and dependence capability. We present a case of zolpidem dependence in a 33-year-old male to emphasize that clinicians should pay close attention to the potential of zolpidem tolerance, abuse and dependence.

Key Word : Zolpidem, Dependence

INTRODUCTION

The use of benzodiazepines (BDZs) in the treatment of insomnia has been declining in recent years as a result of studies documenting a series of deleterious effects (addiction, rebound insomnia, etc.). At the same time, the prescription of non-BDZ hypnotics, such as zolpidem has been increasing substantially. Similar to BDZs, zolpidem reinforces the activity of the inhibitory neurotransmitter g-aminobutyric acid (GABA) by binding to BDZ receptors, which are modulatory sites of the GABA A receptor complex. However, in contrast to BDZs, zolpidem shows selectivity for the σ_1 receptor subtype, which corresponds to GABA A receptors containing the α_1 subunit¹. Zolpidem is able to produce sedation without interfering with the BDZ properties linked

to other receptor subtypes². So zolpidem was considered a safer hypnotic than benzodiazepines because of a lesser liability for abuse and dependence³. However, in recent years, new evidence has revealed that the behavioural effects of zolpidem at higher than recommended doses are generally similar to those of BDZs^{4,5}. Over the last few years, numerous cases of zolpidem abuse or dependence have been reported⁵⁻⁸. The World Health Organization (WHO) considered that the frequency of zolpidem abuse and dependence was similar to that of benzodiazepine. On 15 July 2002, zolpidem was transferred to Schedule IV of the 1971 Convention (for drugs inducing dependence such as benzodiazepines). The aim of this convention was to control both traffic and abuse of psychotropics⁹. We present a case of zolpidem dependence in a 33-year-old male to highlight the need for caution when prescribing this drug.

CASE HISTORY

Mrs. A., 33-year-old Hindu married male presented to psychiatry outpatient department (OPD) with complaints of inability to stop zolpidem use from last 4 months. On evaluation of history it was revealed

Corresponding Author

Satyakam Mohapatra

Mental Health Institute,

S.C.B. Medical College, Cuttack, Odisha.

E mail : satyakgmu@gmail.com

that the patient has history of insomnia 4 months back for which he was prescribed tablet zolpidem 10 mg at bed time by a physician. After 1 week he again complained of decreased sleep. The patient without consulting the physician increased the dose of zolpidem to 20 mg at bed time. After 5 days he again complained of decreased sleep and increased the dose of zolpidem to 30 mg at bedtime. Over the next three months he gradually increased the dose of zolpidem by 10 mg at an interval of 5-7 days . Now he is taking 300mg of zolpidem at bed time every day. He had made several attempts during these 4 months to stop zolpidem, but he failed due to insomnia, restlessness, irritability, myalgia. The patient was admitted. On mental status examination he admitted that he increased the dosage initially to ward off his insomnia; however he started enjoying the high produced by zolpidem and had to increase his dosage gradually in order to experience the same pleasure. Baseline investigations including hemogram, liver and kidney functions were normal. Electrocardiogram was normal. No psychiatric or physical disorder causing insomnia could be found. There was no history of any other substance abuse. He was diagnosed as having zolpidem dependence [Mental and behavioural disorders due to the use of sedatives or hypnotics (zolpidem) (F13.24)] as per International Classification of Diseases - 10th Edition. He was started on chlordiazepoxide 100 mg/day which was gradually tapered-off and stopped in next 15 days. Simultaneously, her zolpidem was also tapered-off and completely stopped in 15 days. After his detoxification from zolpidem he was educated about sleep hygiene measures and the need to abstain from benzodiazepines and other hypnotics. He is in our follow up for last 3 months. He is having normal sleep without any sedative.

DISCUSSION

Despite primary reports of zolpidem safety and minor abuse and dependency capability¹¹⁻¹⁴, recent case reports⁵⁻⁸ including our case showed that zolpidem can exert abuse and dependency. It has been reported that zolpidem pharmacodynamics

and pharmacokinetics may have a crucial role in cases of zolpidem abuse, dependence, and withdrawal syndrome. It is suggested that zolpidem might lose its selectivity on GABA-A receptor and exert the same pharmacological effects as classical benzodiazepines. It has been proposed that possible GABA-A receptor mutations may be a predisposing factor in zolpidem dependency⁵. Several case reports^{8,15} mentioned that zolpidem dependence is more common in individuals with prior history of substance abuse or comorbid substance abuse. But in our case there is no past history or history of comorbid substance abuse. So zolpidem dependence can occur in patients without any history of other substance abuse. We emphasize that prescribers should be aware of zolpidem's dependence potential and its usage should be monitored as in case of benzodiazepines.

REFERENCE

1. Pritchett DB, Sontheimer H, Shivers BD, Ymer S, Kettenmann H, Schofield PR, et al. Importance of novel GABAA receptor subunit for benzodiazepine pharmacology. *Nature*. 1989 338 : 582-585.
2. Mitler MM. Nonselective and selective benzodiazepine receptor agonists where are we today? *Sleep*. 2000. 23 (suppl 1) : S39-S47.
3. Holm KJ & Goa KL. Zolpidem : An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. *Drugs* 2000; 59 : 865-889.
4. Rush CR, Baker RW, Wright K. Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. *Psychopharmacology*. 1999. 144 : 220-233.
5. Liappas IA, Malitas PN, Dimopoulos NP, Gitsa OE, Liappas AI, Nikolaou ChK, et al. Zolpidem dependence case series : possible neurobiological mechanisms and clinical management. *J Psychopharmacol*. 2003 17 : 131-135.
6. Fernandes WH, Pereira YD, O' Tereza S. A case of Zolpidem dependence successfully detoxified with gabapentin. *Indian J Psychiatry* 2013; 55 : 290-2.
7. Sakkas P, Psarros C, Masdrakis V, Liappas J, Christodoulou GN. Dependence on zolpidem : a case report. *Eur Psychiatry*. 1999 Oct; 14(6) : 358-9.
8. Sharan P, Bharadwaj R, Grover S, Padhy SK, Kumar V, Singh J. Dependence syndrome and intoxication delirium associated with zolpidem. *Natl Med J India* 2007; 20 : 180-1.

Mohapatra, et al. : Zolpidem Dependence

9. LRP. Zolpidem : classé comme psychotrope à risque d'abus. *Rev Prescr* 2002; 22 : 819.
10. World Health Organization. *Mental disorders : Glossary and guide to their classification in accordance with the Tenth Revision of the International Classification of Diseases*. Geneva, Switzerland : World Health Organization. 1992
11. Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P. Evidence of zolpidem abuse and dependence: Results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. *Br J Clin Pharmacol*. 2007; 64 : 198-209.
12. Morinan A, Keaney F. Long-term misuse of zopiclone in an alcohol dependent woman with a history of anorexia nervosa: A case report. *J Med Case Rep* 2010; 4 : 403.
13. Huang MC, Lin HY, Chen CH. Dependence on zolpidem. *Psychiatry Clin Neurosci* 2007; 61 : 207-8.
14. Spyridi S, Diakogiannis I, Nimatoudis J, Iacovides A, Kaprinis G. Zolpidem dependence in a geriatric patient : A case report. *J Am Geriatr Soc* 2009; 57:1962-3.
15. Rao RV, Sameer M. Zolpidem dependence. *Indian J Pharmacol*. 2005; 37 : 412-3.